Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2009

View Archived Issues

Boehringer Ingelheim describes Factor Xa inhibitors for the treatment of thrombotic disorders

Nuvo and Covidien sign U.S. agreement for Pennsaid and Pennsaid Plus

Novel 11beta-HSD1and sEH inhibitors presented by GlaxoSmithKline for cardiovascular conditions

AstraZeneca and Dainippon Sumitomo Pharma describe novel TLR receptor modulators

Piclozotan shows preclinical and clinical efficacy in improving PD motor complications

Pennsylvania State University presents D1 dopamine agonist with antiparkinson potential

Phase IIb analyses further delineate linaclotide activity in chronic and IBS-constipation

ExonHit completes patient dosing in phase II clinical trial of EHT-0202 in AD

Abbott initiates enrollment into SPIRIT PRIME trial of Xience Prime coronary stent

CeNeRx completes USD 9 million financing and acquires rights to CXB-909 from Krenitsky

Idera presents update on drug candidate pipeline targeted to toll-like receptors

Roche describes novel FBPase inhibitors as antidiabetics

Teduglutide substudy shows effects on intestinal absorption in short bowel syndrome

Multiple studies of AZD-3355 presented at Digestive Disease Week

Autologous cancer vaccine TAG prolongs stable disease in phase I trial in advanced cancer patients

Akela and Teikoku amend license and codevelopment agreement for Fentanyl Taifun

Safety committee recommends continuation of BioSante's phase III study of LibiGel in HSDD

FDA grants fast track designation to Epeius' Rexin-G for treatment of pancreatic cancer

Ligand commences clinical trial with selective androgen receptor modulator LGD-4033

Antigenics' QS-21 adjuvant used in pivotal phase III malaria vaccine trial

Phase II trial shows elacytarabine may increase survival in late-stage leukemia

Neuromed sells U.S. rights to Exalgo to Mallinckrodt

COMP grants orphan drug designation to Clinuvel's afamelanotide for solar urticaria

FDA approves Novartis' monoclonal antibody Ilaris for children and adults with CAPS

Watson enters agreement to acquire Arrow Group